Study #2015-0353
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination with AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparin
MD Anderson Study Status
Not Accepting
Treatment Agent
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
Description
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-402-0289
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.